Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits
Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the...
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the ...
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.
Eli Lilly's weekly insulin intensifies race with Novo Nordisk
A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the...
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound.
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a sec...
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
These businesses are capitalizing on the future of their respective industries. Eli Lilly is already experiencing untold success amid the GLP-1 inhibitor drug boom, but the nearly 150-year-old comp...
3 No-Brainer Stocks to Buy in September
Eli Lilly is a growth machine that never runs out of opportunities. Novo Nordisk is still gaining momentum.
Eli Lilly Could Become the First $1 Trillion Drug Stock. How Weight-Loss Drugs Can Get It There.
The GLP-1 drug giant's shares have surged this year. Eli Lilly could keep climbing thanks to strong demand for Mounjaro and Zepbound.
Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
Eli Lilly has been rolling out Zepbound in recent months, and demand has been "unbelievable," says the CEO. Sales have been taking off, and that's even without spending aggressively on sales and ma...
Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound
LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.
Hims & Hers Health Stock Takes Hit as Eli Lilly Offers Cheaper Weight-Loss Drug
Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY).
Eli Lilly Launches Cheaper Single-Use Vials of Weight-Loss Drug Zepbound
Eli Lilly (LLY) reached a key supply milestone Tuesday, announcing the launch of single-dose vials of Zepbound, one of the company's popular weight-loss drugs.
Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
CNBC's Joe Kernen reports on the latest news.
Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular inject...
Related Companies